About Angiopoietin-1
Angiopoietin-1 (ANGPT1) is a protein
from Homo sapiens identified by UniProt accession
Q15389, 498 residues long.
MolForge cross-references it against 0 known binders and
534 disease associations.
Target properties
| Protein name | Angiopoietin-1 |
| UniProt accession | Q15389 |
| Gene | ANGPT1 |
| Organism | Homo sapiens |
| Length | 498 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (534)
Diseases linked to this target (Open Targets).
- intraocular pressure measurement · score 0.50
- mean corpuscular volume · score 0.48
- erythrocyte count · score 0.46
- reticulocyte count · score 0.45
- glaucoma · score 0.43
- mean corpuscular hemoglobin concentration · score 0.43
- reticulocyte measurement · score 0.42
- mean corpuscular hemoglobin · score 0.42
- aortic measurement · score 0.41
- open-angle glaucoma · score 0.41
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15389-F1 | alphafold | PREDICTED | 83.10 | — |
Amino-acid sequence (498 residues)
MTVFLSFAFL AAILTHIGCS NQRRSPENSG RRYNRIQHGQ CAYTFILPEH DGNCRESTTD QYNTNALQRD APHVEPDFSS QKLQHLEHVM ENYTQWLQKL ENYIVENMKS EMAQIQQNAV QNHTATMLEI GTSLLSQTAE QTRKLTDVET QVLNQTSRLE IQLLENSLST YKLEKQLLQQ TNEILKIHEK NSLLEHKILE MEGKHKEELD TLKEEKENLQ GLVTRQTYII QELEKQLNRA TTNNSVLQKQ QLELMDTVHN LVNLCTKEGV LLKGGKREEE KPFRDCADVY QAGFNKSGIY TIYINNMPEP KKVFCNMDVN GGGWTVIQHR EDGSLDFQRG WKEYKMGFGN PSGEYWLGNE FIFAITSQRQ YMLRIELMDW EGNRAYSQYD RFHIGNEKQN YRLYLKGHTG TAGKQSSLIL HGADFSTKDA DNDNCMCKCA LMLTGGWWFD ACGPSNLNGM FYTAGQNHGK LNGIKWHYFK GPSYSLRSTT MMIRPLDF
Explore Angiopoietin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets